Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Primary Target

regulation of mucus secretion

4

Histamine H1 receptor

315

Dopamine D2 receptor

297

DNA

278

Bacterial penicillin-binding protein

233

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

Possibly Marketed Outside US

4

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

4

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

2008

4

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Chronic obstructive pulmonary disease

4

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

4

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

4

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

4

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

EVMPD

4

FDA UNII

4

PUBCHEM

4

SMS_ID

4

CAS

3

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

RESPIRATORY SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

COUGH AND COLD PREPARATIONS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Mucolytics

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

3

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 4 of 4 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

CARBOCYSTEINE

740J2QX53R

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 2008

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Oxidative Stress

regulation of mucus secretion

inflammatory response

Conditions:

Chronic obstructive pulmonary disease

S-Carboxymethylcysteine (carbocysteine or SCMC; also available in the lysinate form, SCMC-Lys) is a mucoactive drug, has antioxidant and anti-inflammatory properties. Carbocysteine has been recently recognized as an effective and safe treatment for t...

he long-term management of COPD, able to reduce the incidence of exacerbations and improve patient quality of life. Moreover, carbocysteine was effective in counteracting some symptoms associated with cancer cachexia. Preclinical and clinical studies have demonstrated that the antioxidant and anti-inflammatory properties of carbocysteine are more important than mucolysis itself for its therapeutic efficacy. Therefore, carbocysteine may be able to reverse the oxidative stress associated with several chronic inflammatory diseases, such as cardiovascular diseases and neurodegenerative disorders.

CARBOCYSTEINE LYSINE MONOHYDRATE

QA5ZP9OL3E

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 2008

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Oxidative Stress

regulation of mucus secretion

inflammatory response

Conditions:

Chronic obstructive pulmonary disease

S-Carboxymethylcysteine (carbocysteine or SCMC; also available in the lysinate form, SCMC-Lys) is a mucoactive drug, has antioxidant and anti-inflammatory properties. Carbocysteine has been recently recognized as an effective and safe treatment for t...

he long-term management of COPD, able to reduce the incidence of exacerbations and improve patient quality of life. Moreover, carbocysteine was effective in counteracting some symptoms associated with cancer cachexia. Preclinical and clinical studies have demonstrated that the antioxidant and anti-inflammatory properties of carbocysteine are more important than mucolysis itself for its therapeutic efficacy. Therefore, carbocysteine may be able to reverse the oxidative stress associated with several chronic inflammatory diseases, such as cardiovascular diseases and neurodegenerative disorders.

CARBOCYSTEINE SODIUM

2UZV9PEJ2N

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 2008

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Oxidative Stress

regulation of mucus secretion

inflammatory response

Conditions:

Chronic obstructive pulmonary disease

S-Carboxymethylcysteine (carbocysteine or SCMC; also available in the lysinate form, SCMC-Lys) is a mucoactive drug, has antioxidant and anti-inflammatory properties. Carbocysteine has been recently recognized as an effective and safe treatment for t...

he long-term management of COPD, able to reduce the incidence of exacerbations and improve patient quality of life. Moreover, carbocysteine was effective in counteracting some symptoms associated with cancer cachexia. Preclinical and clinical studies have demonstrated that the antioxidant and anti-inflammatory properties of carbocysteine are more important than mucolysis itself for its therapeutic efficacy. Therefore, carbocysteine may be able to reverse the oxidative stress associated with several chronic inflammatory diseases, such as cardiovascular diseases and neurodegenerative disorders.

CARBOCYSTEINE LYSINE

1D1Y95PXXA

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 2008

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Oxidative Stress

regulation of mucus secretion

inflammatory response

Conditions:

Chronic obstructive pulmonary disease

S-Carboxymethylcysteine (carbocysteine or SCMC; also available in the lysinate form, SCMC-Lys) is a mucoactive drug, has antioxidant and anti-inflammatory properties. Carbocysteine has been recently recognized as an effective and safe treatment for t...

he long-term management of COPD, able to reduce the incidence of exacerbations and improve patient quality of life. Moreover, carbocysteine was effective in counteracting some symptoms associated with cancer cachexia. Preclinical and clinical studies have demonstrated that the antioxidant and anti-inflammatory properties of carbocysteine are more important than mucolysis itself for its therapeutic efficacy. Therefore, carbocysteine may be able to reverse the oxidative stress associated with several chronic inflammatory diseases, such as cardiovascular diseases and neurodegenerative disorders.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1